Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Editas Medicine, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 2.62 · gapped above the open, then crossed back over prior close. High/low 2.83 at 6:00 am ET, 2.60 at 3:30 pm ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“For example, certain patent applications licensed to us by Broad are co-owned with NIH.”
FILING10-K0001650664-26-000017cik 0001650664
“In connection with our collaboration with BMS, we have received an aggregate of $159.0 million in payments, which have primarily consisted of the initial upfront and amendment payments, development milestone payments, research funding support, and certain opt-in fees.”
FILING10-K0001650664-26-000017cik 0001650664
“In addition, in December 2023, we and Vertex Pharmaceuticals Incorporated ("Vertex") entered into a license agreement (the "Vertex License Agreement"), under which Vertex obtained a non-exclusive license for our Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of SCD and TDT, including Vertex's CASGEVY TM (exagamglogene autotemcel).”
FILING10-K0001650664-26-000017cik 0001650664
“We have financed our operations primarily through public offerings of our common stock, our research collaboration with Bristol Myers Squibb Company ("BMS") through its wholly owned subsidiary, Juno Therapeutics, Inc. , payments under our former strategic alliance with Allergan Pharmaceuticals International Limited (together with its affiliates, "Allergan"), which was terminated in August 2020, payments received under our purchase and sale agreement with DRI Healthcare Acquisitions LP, and payments under our license agreement with Vertex Pharmaceuticals, Incorporated ("Vertex").”
FILING10-K0001650664-26-000017cik 0001650664
“We are also party to a non-exclusive collaboration and licensing agreement with Immatics to combine gamma-delta T cell adoptive cell therapies and gene editing for the treatment of cancer.”
FILING10-K0001650664-26-000017cik 0001650664
“Pursuant to the Cas9-I License Agreement, Harvard and Broad granted us an exclusive, worldwide, royalty-bearing, sublicensable license to the Harvard/Broad Cas9-I Patent Rights to make, have made, use, sell, offer for sale, have sold, import, and export products and services in the field of the prevention and treatment of human disease, subject to certain limitations and retained rights.”
FILING10-K0001650664-26-000017cik 0001650664
“In May 2021, we entered into a common stock sales agreement with TD Securities (USA) LLC (as successor to Cowen and Company, LLC) ("TD Cowen") under which we from time to time can issue and sell shares of our common stock through TD Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million.”
FILING10-K0001650664-26-000017cik 0001650664
“In October 2024, we entered into an agreement (the "DRI Agreement") with a wholly owned subsidiary of DRI Healthcare Trust ("DRI") providing for an upfront cash payment by DRI to us of $57.0 million.”
FILING10-K0001650664-26-000017cik 0001650664
“In May 2015, we entered into a collaboration and license agreement with Juno Therapeutics, a subsidiary of BMS, for the research and development of engineered T cells with CARs and eTCRs that have been genetically modified to recognize and kill other cells.”
FILING10-K0001650664-26-000017cik 0001650664
“The March 2017 amendment to the Cas9-I License Agreement included a license to Rockefeller's rights in such patents and patent applications.”
FILING10-K0001650664-26-000017cik 0001650664
“For example, pursuant to our license agreements with The Broad Institute, Inc. ("Broad"), and Broad and the President and Fellows of Harvard College ("Harvard"), the licensors may, under certain circumstances, grant a license to the patents that are the subject of such license agreements to a third party.”
FILING10-K0001650664-26-000017cik 0001650664
“the cost to obtain licenses to intellectual property, such as those with Harvard University, or Harvard, The Broad Institute, Inc., or Broad Institute, Editas Medicine, Inc., or Editas, and Bio Palette Co., Ltd., or Bio Palette, and related future payments should certain success, development and regulatory milestones be achieved;”
FILING10-K0001193125-26-065194cik 0001745999disclosed by BEAM
“We have primarily financed our operations through various equity financings, payments received under our research collaboration with BMS, our former strategic alliance with Allergan Pharmaceuticals International Limited (together with its affiliates, "Allergan"), which was terminated in August 2020, payments received under the DRI Agreement in connection with the Vertex License Agreement, and payments under the Vertex License Agreement.”
FILING10-K0001650664-26-000017cik 0001650664
Watchlist prices, news filtered to it, and its next report on your desk.
Editas Medicine, Inc. has 5 disclosed suppliers and 8 disclosed customers. Each one is named in an SEC filing, either Editas Medicine, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
EDIT (Editas Medicine, Inc.) has 5 disclosed suppliers and 8 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: BEAM −3.73%, in healthcare.